clinical trials for glp-1 obesity meds actively recruiting From Post to Prescription: How is Social Media shaping the conversation on and on Pharmacotherapy Obesity? The everything drugs: from weight

In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity

GLP-1

Brand names are referenced for educational context only and do not indicate that a specific branded product will be prescribed

Improve blood sugar regulation

Doctors can prescribe some diabetes drugs off-label for weight loss